Login / Signup

Protective immune trajectories in early viral containment of non-pneumonic SARS-CoV-2 infection.

Kami PekayvazAlexander LeunigRainer W J KaiserMarkus JoppichSophia BrambsAleksandar JanjicOliver PoppDaniel NixdorfValeria FumagalliNora SchmidtVivien PolewkaAfra AnjumViktoria KnottenbergLuke EiversLucas Esteban WangeChristoph GoldMarieluise KirchnerMaximilian MuenchhoffJohannes Christian HellmuthClemens SchererRaquel Rubio-AceroTabea EserFlora DeákKerstin PuchingerNiklas KuhlAndreas LinderKathrin SaarLukas TomasChristian SchulzAndreas WieserWolfgang EnardInge KroidlChristof GeldmacherMichael von Bergwelt-BaildonOliver T KepplerMathias MunschauerMatteo IannaconeRalf ZimmerPhilipp MertinsNorbert HubnerMichael HoelscherSteffen MassbergKonstantin StarkLeo Nicolai
Published in: Nature communications (2022)
The antiviral immune response to SARS-CoV-2 infection can limit viral spread and prevent development of pneumonic COVID-19. However, the protective immunological response associated with successful viral containment in the upper airways remains unclear. Here, we combine a multi-omics approach with longitudinal sampling to reveal temporally resolved protective immune signatures in non-pneumonic and ambulatory SARS-CoV-2 infected patients and associate specific immune trajectories with upper airway viral containment. We see a distinct systemic rather than local immune state associated with viral containment, characterized by interferon stimulated gene (ISG) upregulation across circulating immune cell subsets in non-pneumonic SARS-CoV2 infection. We report reduced cytotoxic potential of Natural Killer (NK) and T cells, and an immune-modulatory monocyte phenotype associated with protective immunity in COVID-19. Together, we show protective immune trajectories in SARS-CoV2 infection, which have important implications for patient prognosis and the development of immunomodulatory therapies.
Keyphrases